Candel Therapeutics (CADL) Share-based Compensation (2020 - 2023)
Historic Share-based Compensation for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to $939000.0.
- Candel Therapeutics' Share-based Compensation rose 4810.73% to $939000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $3.1 million, marking a year-over-year increase of 3398.35%. This contributed to the annual value of $5.3 million for FY2024, which is 7185.38% up from last year.
- Latest data reveals that Candel Therapeutics reported Share-based Compensation of $939000.0 as of Q4 2023, which was up 4810.73% from $686000.0 recorded in Q3 2023.
- Over the past 5 years, Candel Therapeutics' Share-based Compensation peaked at $1.9 million during Q3 2021, and registered a low of -$446000.0 during Q4 2021.
- Over the past 4 years, Candel Therapeutics' median Share-based Compensation value was $686000.0 (recorded in 2023), while the average stood at $700000.0.
- Over the last 5 years, Candel Therapeutics' Share-based Compensation had its largest YoY gain of 220000.0% in 2021, and its largest YoY loss of 12544.21% in 2021.
- Over the past 4 years, Candel Therapeutics' Share-based Compensation (Quarter) stood at $1.8 million in 2020, then crashed by 125.44% to -$446000.0 in 2021, then surged by 242.15% to $634000.0 in 2022, then skyrocketed by 48.11% to $939000.0 in 2023.
- Its Share-based Compensation stands at $939000.0 for Q4 2023, versus $686000.0 for Q3 2023 and $733000.0 for Q2 2023.